A phase 1b randomized, head-to-head study suggests that the investigational VEGF/Ang2 bispecific antibody OLN324 may offer ...
ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with ...
Many retinal diseases begin long before patients experience noticeable vision loss.Clinicians frequently manage patients with ...
YAG capsulotomy is a laser procedure used to treat posterior capsule opacification (PCO), a common cause of blurred vision ...
Positive topline results from the phase 3 GLOW2 trial suggest that tarcocimab tedromer (Zenkuda), an investigational anti–vascular endothelial growth factor (VEGF) biologic, may offer durable disease ...
The vision-screening sector has delivered steady growth over the past several years. One study shows these kiosks can reach ...
Brain-computer interfaces could soon restore vision for the blind, revolutionizing human interaction with technology.
VG801 shows encouraging preliminary efficacy in the ongoing Phase 1/2 trial, with consistent functional improvements in best-corrected visual ...
The European Stroke Organization issued its first recommendations on the management of visual and visual perceptual disorders after stroke, calling for systematic early screening and wider ...
Even in an era of remarkable therapeutics for neovascular age-related macular degeneration, there remains a lack of therapies ...
Children with neurofibromatosis type 1 (NF1) who have more posteriorly located optic pathway gliomas (OPGs) are more likely to experience central precocious puberty (CPP), according to findings of a ...
Vision loss exists on a wide spectrum, and low vision is very different from total blindness.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results